Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.

Frontiers in immunology - 1 Jan 2023

Gonzalez-Montes Yolanda, Rodriguez-Romanos Rocío, Villavicencio Alicia, Osca-Gelis Gemma, González-Bártulos Marta, Llopis Francesca, Clapes Victòria, Oriol Albert, Sureda Anna, Escoda Lourdes, Sarrà Josep, Garzó Ana, Lloveras Natàlia, Díez Isabel, Granada Isabel, Gallardo David

Abstract excerpt

Immune dysfunction in patients with multiple myeloma (MM) affects both the innate and adaptive immune system. Molecules involved in the immune checkpoint pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. However, few data are available concerning the role of these molecules in predicting the kinetics of progression of MM. We retrospectively analysed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CTLA-4 Antigen
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Myeloma

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 37122695
DOI: 10.3389/fimmu.2023.1158105
PMCID: PMC10143497

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.PMID 37122695Read ↗

CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.Semantic proximity Read ↗

Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population.Semantic proximity Read ↗

Association between BCL2 interacting protein 3 like (BNIP3L) genetic polymorphisms and the risk of multiple myeloma in China.Semantic proximity Read ↗

TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.Semantic proximity Read ↗

Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma.Semantic proximity Read ↗

Increased exhausted CD8+ T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma.Semantic proximity Read ↗

Telomere length and hTERT genetic variants as potential prognostic markers in multiple myeloma.Semantic proximity Read ↗

Prognostic relevance of telomere length and telomerase reverse transcriptase variant (rs2242652) on the multiple myeloma patients.Semantic proximity Read ↗

Genetically determined telomere length and multiple myeloma risk and outcome.Semantic proximity Read ↗

Polymorphisms within genes encoding Ikaros family proteins IKZF1 and IKZF3 in multiple myeloma patients treated with thalidomide.Semantic proximity Read ↗

Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival.Semantic proximity Read ↗

Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.